
News|Articles|January 29, 2024
Alternative buffer management strategies to achieve downstream process improvements
Author(s)Avantor
Buffers are used in great quantities when producing monoclonal antibodies (mAbs), and many biopharmaceutical companies — even large ones — do not have the processing capacity or infrastructure in-house to handle these large volumes. Whether it’s providing quality, pre-weighed, GMP-compliant raw materials or the entire buffer preparation step, there are options available to optimize your process.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Jubilant Biosys Announces New Facility in India
2
Gene Therapy, Rare Diseases, and Transfer RNA
3
Medable Presents AI Agent for Automating Trial Master File Processes at JP Morgan Healthcare Conference
4
Personalized Medicine Vs. Precision Medicine
5